1型糖尿病治疗中的脂肪来源间充质基质/干细胞

Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment.

作者信息

Sood Vanshika, Ricioli Hannah, Njoku George Chigozie, Primavera Rosita, Dietrich Susana, Thakor Avnesh S, Pociot Flemming, Yarani Reza

机构信息

Translational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.

Department of Science & Health, DIS Study Abroad in Scandinavia, Copenhagen, Denmark.

出版信息

Commun Biol. 2025 Jul 23;8(1):1094. doi: 10.1038/s42003-025-08244-z.

DOI:10.1038/s42003-025-08244-z

PMID:40702360

Abstract

Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in animal models and clinical trials have revealed decreased insulin dependence, increased β cell mass, and improved islet graft acceptance. Despite their potential, challenges in quality control, small-scale investigations, functional heterogeneity, and standardization limit the application of these therapies. This review synthesizes the current knowledge and recent outcomes of ADMSC therapies in treating T1D and highlights areas that need further investigation.

摘要

脂肪组织来源的间充质基质/干细胞（ADMSCs）是1型糖尿病（T1D）的一种新型治疗手段。ADMSCs的吸引力在于其免疫调节活性、再生特性以及相对容易获取。在动物模型和临床试验中的ADMSC治疗已显示出胰岛素依赖性降低、β细胞量增加以及胰岛移植接受度提高。尽管它们具有潜力，但质量控制、小规模研究、功能异质性和标准化方面的挑战限制了这些疗法的应用。本综述综合了ADMSC治疗T1D的当前知识和近期成果，并突出了需要进一步研究的领域。